Immutep's phase 3 failure shocks investors amid broader biotech layoffs

Immutep, an Australian biotech company, faced an unexpected setback as its LAG-3 immunotherapy candidate failed in a phase 3 clinical trial, surprising analysts and causing a sharp decline in its stock.